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864 Simpson et alMethods: A randomized, placebo-controlled, double-blind, phase 2 study. Adults with moderate-to-severe
AD were required to use TCS twice daily and then randomized (1:1:1:1) to lebrikizumab 125 mg single
dose, lebrikizumab 250 mg single dose, lebrikizumab 125 mg every 4 weeks for 12 weeks, or placebo every
4 weeks for 12 weeks, after a 2-week TCS run-in. The primary endpoint was percentage of patients
achieving Eczema Area and Severity Index (EASI)-50 at week 12.Results: In total, 209 patients received the study drug. At week 12, significantly more patients achieved
EASI-50 with lebrikizumab 125 mg every 4 weeks (82.4%; P = .026) than placebo every 4 weeks (62.3%);
patients receiving a single dose of lebrikizumab showed no statistically significant improvements in EASI-50
compared with placebo. Adverse events were similar between groups (66.7% all lebrikizumab vs 66.0%
placebo) and mostly mild or moderate.Limitations: Protocol-mandated twice daily TCS treatment limits our understanding of the efficacy of
lebrikizumab as a monotherapy. The short study duration did not enable long-term efficacy or safety
evaluations.Conclusion: When combined with TCS, lebrikizumab 125 mg taken every 4 weeks led to a significant
improvement and was well tolerated in patients with moderate-to-severe AD. ( J Am Acad Dermatol
2018;78:863-71.)
Key words: anti-IL-13; atopic dermatitis; EASI; lebrikizumab; pruritus; topical corticosteroids.CAPSULE SUMMARY
d Interleukin 13 (IL-13) is overexpressed in
patients with atopic dermatitis (AD).
d Lebrikizumab, a monoclonal antibody
against IL-13, was superior to placebo in
patients with AD when administered
subcutaneously every 4 weeks along
with topical corticosteroids.
d IL-13 inhibition with lebrikizumab could
reduce the need for oral
immunosuppressive therapy for patients
with AD.Atopic dermatitis (AD) is a
chronic skin disorder charac-
terized by intensely pruritic,
eczematous lesions accompa-
nied by a disrupted skin bar-
rier and type 2 inflammation.1
AD is one of the most com-
mon dermatologic diagnoses
worldwide and its burden is
multidimensional, impacting
sleep, psychosocial activities,
and health-related quality of
life.2-4 In moderate-to-severe
AD, potent topical corticoste-
roids (TCS), calcineurin in-
hibitors, phototherapy, and
conventional immunosup-
pressive medications (eg, cyclosporine) are often
required. However, efficacy of topical therapies can
be limited, and their frequent use is cumbersome and
carries the risk for side effects.5 Standard systemic
treatments used for moderate-to-severe disease also
carry significant risks.6
Interleukin (IL)-13 plays a central role in type 2
inflammation, and certain gene polymorphisms are
associated with increased risk for AD.7 There is
increased expression of IL-13 mRNA in skin biopsy
specimens from patients with AD relative to healthy
controls, and levels of IL-13 mRNA expression
correlate with AD disease severity.8,9 Furthermore,
overexpression of IL-13 has been shown to reduce
epithelial integrity via the down-regulation of keyskin barrier components.10,11
Treatment of AD with sys-
temic agents such as cyclo-
sporine can decrease skin
IL-13 levels,12 and recent tri-
als have reported improved
clinical responses in patients
with moderate-to-severe AD
treated with dupilumab, a
monoclonal antibody against
IL-4Ra, which inhibits IL-13/
IL-4 signaling.13,14 Together,
these data support IL-13 as a
key mediator in AD.
In theory, targeting the
most central pathologic me-
diators in AD might maxi-mize efficacy and limit toxicity. Lebrikizumab is a
monoclonal antibody that binds specifically to solu-
ble IL-13 with high affinity, preventing IL-13Ra1/IL-
4Ra heterodimerization and subsequent
signaling.15,16 Lebrikizumab has previously been
investigated for the treatment of asthma, and data
have accumulated from 11 randomized clinical trials
involving 4411 individuals.15,17-20 After promising
phase 2b data in uncontrolled asthma, only 1 of the 2
phase 3 studies in severe adult asthma showed a
statistically significant reduction in asthma exacer-
bations in the primary analysis population.
Nonetheless, based on IL-13’s involvement in multi-
ple pathways important to AD pathogenesis, lebri-
kizumab represents a novel targeted therapy in AD.
Abbreviations used:
AD: atopic dermatitis
ADIQ: Atopic Dermatitis Impact
Questionnaire
AE: adverse event
BSA: body surface area
EASI: Eczema Area and Severity Index
IGA: Investigator Global Assessment
IL-4: interleukin-4
IL-13: interleukin-13
SCORAD: SCORing Atopic Dermatitis
TCS: topical corticosteroids
VAS: Visual Analog Scale
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tigated the efficacy and safety of lebrikizumab,
compared with placebo, as an add-on therapy to
TCS in adults with moderate-to-severe AD.
METHODS
Study design
TREBLE was a randomized, placebo-controlled,
double-blind, phase 2 study conducted at 62 centers.
It included a 2-week TCS run-in period before the 12-
week treatment period. Patients were instructed with
daily e-Diary reminders to apply medium-potency
TCS (0.1% triamcinolone acetonide) to all lesional
skin during run-in and study treatment. For lesions
affecting the face or intertriginous areas, 2.5% hy-
drocortisone could be used. TCS was included in the
regimen because, historically, studies on biologic
therapies in a monotherapy setting have led to high
dropout/imputed patient failure rates, in particular
because of disease severity. In addition, add-on TCS
treatment reflects real-life clinical practice in patients
with moderate-to-severe AD. Further details about
study design, pharmacokinetics, outcome measures,
and statistical analyses are provided in the online
Supplementary Appendix (available at http://www.
jaad.org). The study was undertaken in accordance
with Good Clinical Practice guidelines and adhered
to the Declaration of Helsinki. All study documents
and procedures were approved by the appropriate
institutional review boards and ethics committees at
each study site and each patient provided written
informed consent before study participation. An
internal monitoring committee was incorporated to
monitor patient safety throughout the study.
Patients
Eligible patients were aged 18-75 years and had
a diagnosis of moderate-to-severe AD with an
inadequate response to TCS ($1-month history
within 3 months before screening) and regular
emollient. Other key inclusion criteria wereEczema Area and Severity Index (EASI) $14 and
Investigator Global Assessment (IGA) score $3 at
screening and end of the run-in period and AD
involvement of $10% of body surface area (BSA)
and Pruritus Visual Analog Scale (VAS) score $3
(measured as part of SCORing Atopic Dermatitis
[SCORAD]) at screening.
Exclusion criteria included use of topical calci-
neurin inhibitors; recent systemic immunosuppres-
sive therapies or phototherapy; and evidence of
other skin conditions, including T-cell lymphoma
or allergic contact dermatitis.
Randomization
Patients were randomized 1:1:1:1 to receive leb-
rikizumab 125 mg single dose at baseline, 250 mg
single dose at baseline, 125 mg once every 4 weeks,
or placebo every 4 weeks for 12 weeks.
Procedures
The 12-week treatment period was followed by
an 8-week safety follow-up period, during which
patients could apply TCS as needed. Disease severity
assessments included EASI, IGA, and SCORAD;
patient-reported outcome data were collected by
using the Dermatology Life Quality Index and AD
Impact Questionnaire (ADIQ).21
Outcomes
The primary endpoint was the percentage of
patients achieving a 50% reduction in EASI score
from baseline (EASI-50) at week 12. This EASI-50
also equates to a minimum of a 7-point improvement
from the required baseline score $14 in this study,
which is above the minimum clinically important
difference of 6.6 points.22 Key secondary endpoints
included the percentages of patients achieving EASI-
75, IGA score of 0 or 1, and SCORAD-50 at week 12.
Safety outcomes, including treatment-emergent
adverse events (AEs) and serious AEs, were moni-
tored at each visit from baseline to week 20.
Eosinophil-associated AEs were also monitored.
Statistical analyses
Primary and secondary efficacy analyses included
all patients who were randomized and received $1
dose of study drug and were analyzed according to
the treatment assigned at randomization. Safety
analyses included all patients who received $1
dose of study drug and were analyzed according
to the treatment received. The Cochran-Mantele
Haenszel x2 test was used to compare the pro-
portions of patients with EASI-50 at week 12 in
each of the lebrikizumab groups versus placebo,
stratified by randomization stratification factor
Table I. Baseline characteristics and demographics of patients with atopic dermatitis included in study
Characteristic
Lebrikizumab 125 mg
single dose, n = 52
Lebrikizumab 250 mg
single dose, n = 53
Lebrikizumab 125 mg
Q4W, n = 51 Placebo, n = 53
Mean age, y (SDv) 34.9 (12.7) 34.4 (12.3) 36.6 (12.3) 38.7 (13.2)
Male, n (%) 34 (65.4) 31 (58.5) 35 (68.6) 36 (67.9)
Race, n (%)
White 36 (69) 43 (81) 36 (71) 35 (66)
Asian 13 (25) 9 (17) 15 (29) 16 (30)
Other 3 (6) 1 (2) 0 2 (4)
Mean Rajka-Langeland (SDv) 8.50 (0.73) 8.49 (0.67) 8.34 (0.87) 7.96 (1.06)
Mean EASI (SDv) 24.6 (11.1) 26.3 (12.2) 26.9 (11.7) 23.6 (9.2)
Mean SCORAD (SDv) 56.5 (13.4) 58.9 (13.5) 60.8 (13.6) 59.2 (12.0)
Mean IGA (SDv) 3.2 (0.4) 3.3 (0.5) 3.2 (0.42) 3.2 (0.4)
IGA = 4, n (%) 10 (19) 15 (28) 11 (22) 11 (21)
Mean % BSA affected (SDv) 44.2 (21.3) 50.5 (24.7) 48.5 (22.7) 43.4 (22.0)
BSA, Body surface area; EASI, Eczema Area Severity Index; IGA, Investigator Global Assessment; Q4W, every 4 weeks; SCORAD, SCORing Atopic
Dermatitis; SDv, standard deviation.
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Europe, and other). Patients missing an EASI score
at week 12 were considered nonresponders.
RESULTS
Trial patients
Overall, 209 patients received study drug (n = 53
placebo; n = 156 lebrikizumab) (Supplemental Fig 1;
available at http://www.jaad.org). Baseline charac-
teristics of patients were similar across treatment
groups (Table I). There was a high compliance rate
of TCS use among all treatment groups, with TCS
used on average from baseline to week 12 on 86.8%
of days for patients taking the 125-mg single dose,
86.7% of days for patients taking the 250-mg single
dose, 91.9% of days for patients taking the 125-mg
dose every 4 weeks, and 88.2% of days for patients
taking placebo. Further details of the results are
provided in the online Supplementary Appendix.
Primary outcome
At week 12, significantly more patients in the
lebrikizumab 125 mg every 4 weeks group achieved
EASI-50 compared with placebo (82.4% vs 62.3%;
P = .026) (Fig 1, A). However, the response in the
lebrikizumab single dose groups was not statistically
significant at week 12. In the every 4 weeks arm, the
response curve showed an upward sloping trajectory
in the final weeks of treatment (Fig 2, A). Notably,
patients in the placebo group, with protocol-
mandated twice daily TCS application, showed a
high response rate, with 62.3% of patients exhibiting
an EASI-50 response at week 12.
Other AD severity measures
The proportion of patients achieving an EASI-75
response at week 12 was significantly greater in the125 mg every 4 weeks group (54.9%; P = .036)
compared with placebo (34.0%) but did not
achieve statistical significance in the 125 mg and
250 mg single dose groups (Fig 1, B). As with the
EASI-50 response, patients in the 125 mg every
4 weeks group showed continued improvement in
EASI-75 over the final weeks of the treatment
period (Fig 2, B).
The percentage of patientswho achieved an IGAof
0or 1 atweek12washigher in all lebrikizumabgroups
compared with placebo (Fig 1, C; Fig 2, C ), but while
there was a trend toward statistical significance with
the 125 mg every 4 weeks group compared with
placebo (33.3% vs 18.9%; P = .098), single doses did
not achieve statistical significance (Supplemental
Table I; available at http://www.jaad.org).
SCORAD-50 at week 12 was achieved by more
patients in the lebrikizumab 125 mg every 4 weeks
group (51.0%; P = .012) and 250 mg single dose
group (47.2%; P = .030) than the placebo group
(26.4%) (Fig 1, D; Fig 2, D). The greatest reduction in
BSA affected at week 12 was observed in the
lebrikizumab 125 mg every 4 weeks group (57.7%
reduction). Because there were also improvements
in BSA affected in the placebo group (47.4%),
placebo-corrected efficacy for BSA was not statisti-
cally significant (P = .38).Patient-reported symptoms and quality of life
There were adjusted mean percent reductions
from baseline pruritus VAS of 34.9%, 32.8%, and
40.7% in the lebrikizumab 125 mg single dose,
250 mg single dose, and 125 mg every 4 weeks
groups, respectively (Fig 3, A). The placebo group
also showed reductions from baseline pruritus VAS
(27.5%), which resulted in the placebo-corrected
efficacy not being statistically significant (P = .40
A B
C D
*P < .05 vs placebo *P < .05 vs placebo
Fig 1. Proportion of atopic dermatitis patients achieving (A) a 50% reduction of Eczema Area
and Severity Index, (B) a 75% reduction of Eczema Area and Severity Index, (C) an Investigator
Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing Atopic Dermatitis at week 12
of lebrikizumab treatment. Q4W, Every 4 weeks; SD, single dose.
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and P = .13 [125 mg every 4 weeks]) (Supplemental
Table I; available at http://www.jaad.org).
Improvements in pruritus VAS during the 2-week
TCS run-in were quantitatively larger, in percent-
age terms, than improvements in overall disease
severity measures (Supplemental Table II).
There were also improvements in sleep loss VAS,
with higher mean reductions from baseline in the
lebrikizumab 125 mg single dose (53.1%; P = .029),
250mgsingledose (47.2%;P= .076), and125mgevery
4 weeks (53.6%; P = .023) groups than in the placebo
group (22.6%) (Fig 3, B; Supplemental Table I).
Lebrikizumab groups showed numerical im-
provements, relative to placebo, in ADIQ and
Dermatology Life Quality Index scores from baseline
to week 12, with ADIQ showing borderline statistical
significance for the 125 mg every 4 weeks group
(P = .057), but results were otherwise not statistically
significant (Fig 3, C and D; Supplemental Table I).Safety
Lebrikizumab was well tolerated, and there
were no imbalances in proportions of patients
reporting AEs, serious AEs, events leading to
discontinuation, and overall infections when
comparing all lebrikizumab-treated patients with
placebo (Supplemental Table III; available at
http://www.jaad.org). There were no dose-
response relationships in adverse events. Three
(2%) patients in the lebrikizumab group (all doses
combined) and 1 (2%) patient in the placebo
group experienced an AE that led to withdrawal
from study. There were no deaths, anaphylactic
reactions, malignancies, or protocol-defined para-
sitic or targeted intracellular infections of interest.
Injection site reactions occurred infrequently (1.3%
all lebrikizumab groups and 1.9% placebo group);
all events were nonserious and lasted a median of
1-3 days.
A B
D
Fig 2. Proportion of atopic dermatitis patients receiving lebrikizumab achieving (A) a 50%
reduction of Eczema Area and Severity Index, (B) a 75% reduction of Eczema Area and Severity
Index, (C) an Investigator Global Assessment of 0 or 1, and (D) a 50% reduction of SCORing
Atopic Dermatitis over time. Q4W, Every 4 weeks; SD, single dose.
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Lebrikizumab provided a treatment benefit on top
of rigorous TCS therapy in patients with moderate-
to-severe AD who had an inadequate response to
TCS. The study met its primary endpoint, with a
statistically greater proportion of patients in the
lebrikizumab 125 mg every 4 weeks group achieving
an EASI-50 response compared with placebo. The
upward sloping response curves over the final weeks
of the treatment period suggest that the response
plateau might not have been reached by week 12 for
lebrikizumab 125 mg every 4 weeks, and that a
longer treatment duration might lead to improved
efficacy. Although improvements with the single
doses were not statistically significant at week 12,
the significant responses observed with the highest
lebrikizumab dose (125 mg every 4 weeks) might
indicate a dose-response relationship.
Dosing within this study was based largely on
experience from the lebrikizumab asthma program
and the objective of characterizing both dose-
response relationships and dosing frequencyrequirements in AD. The dose-response relation-
ships observed across multiple endpoints and the
trends toward improved efficacy with increasing
dose and duration suggest that further increases in
the dose or treatment duration could improve
efficacy. Notably, the lebrikizumab 250 mg single
dose group showed numerically higher responses at
earlier time points for several outcomes, suggesting
the potential benefit of either higher dosing (eg,
250 mg every 4 weeks) or a loading dose. The
observed differences in the lebrikizumab dose-
response relationship between forced expiratory
volume in 1 second in asthma patients17 and EASI
and IGA endpoints in AD patients suggest that AD
might require higher doses of lebrikizumab to
achieve a response plateau. This would suggest a
higher IL-13 burden in AD than in asthma. Further
studies in AD will be required to confirm whether
additional clinical benefit can be observed with
tailored dosing.
Lebrikizumab was generally well tolerated, and
AE rates were similar between treatment groups.
A B
C D
Fig 3. Adjusted mean percent change from baseline in (A) pruritus Visual Analog Scale, (B)
sleep loss Visual Analog Scale, (C) Atopic Dermatitis Impact Questionnaire, and (D)
Dermatology Life Quality Index over time in atopic dermatitis patients receiving lebrikizumab.
Q4W, Every 4 weeks; SD, single dose.
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the extensive asthma program.15,17-20 Previously
reported increases in peripheral blood eosinophil
counts with lebrikizumab treatment are possibly due
to decreased eosinophil trafficking from the blood to
the airways as a result of reduced chemotaxis by
blocking IL-13 activity.15,20 In the TREBLE study,
although eosinophil-associated AEs occurred only
among lebrikizumab-treated patients, they were
reported infrequently (n = 5 [3.2%]), all events were
nonserious, and none were associated with clinical
signs or symptoms, or resulted in dose reductions or
treatment discontinuation.
The study protocol required twice daily TCS
during the 2-week run-in period, and patients were
only eligible for randomization if they manifested
sufficient AD severity after this run-in. Although
patients included in this study had a history of
inadequate control by TCS, this TCS run-in nonethe-
less led to disease improvement, with lower baseline
AD severity scores, especially itch. Although there is
rationale for such a design, it does potentially leave
less room for disease improvement than without a
run-in period.During the treatment period, patients continued
twice-daily application of TCS, with daily e-Diary
reminders, achieving an 88% compliance rate. TCS
application might explain the substantial response
observed in placebo and could also have attenuated
placebo-corrected efficacy. Prolonged and frequent
TCS use has been shown to result in progressive
improvements in AD, but most guidelines suggest
limiting daily use to avoid AEs.23-25 However, while
daily (not chronic) TCS use is typically recommen-
ded for acute lesions,5 this proof-of-concept study
sought to understand the potential efficacy of
lebrikizumab in addition to continuous TCS and
not to assess TCS-sparing. The chosen regimen is
consistent with TCS labeling and was used because
of regulatory concerns of off-label usage at a lower
frequency than mandated by product labeling. It was
also recognized that alternate designs could have led
to substantial patient dropout and imputed patient
failure within the control arm. Indeed, studies of
biologic therapies in a monotherapy setting have led
to dropout/imputed patient failure rates of ;50%
within the control arm13; in contrast, the dropout rate
of the placebo arm in this study was 13%.
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prolonged and frequent TCS use, there were still
significant improvements, particularly in AD signs
(EASI) and global scores (SCORAD) after addition of
lebrikizumab.
Dupilumab, an IL-4Ra monoclonal antibody,
demonstrated efficacy in patients with moderate-
to-severe AD and has been recently approved for
use in AD patients. IL-4Ra is a receptor subunit for
both IL-4 and IL-13 signaling. Studies of dupilumab
in AD patients provide insight into the potential of
IL-13 blockade to treat AD, with the caveat that the
relative importance of IL-4 compared with IL-13 in
AD has not been established. Both IL-13 and IL-4
share overlapping biology and effector func-
tions.26,27 Given such high overlap in biology,
blockade of IL-13 alone could potentially provide
comparable improvements in AD to blockade of IL-
13 and IL-4 in combination, with a more specific
targeted action.
Targeting a soluble cytokine such as IL-13 might
also offer the advantage of a linear pharmacokinetic
profile, with resulting improvements in sustained
target coverage and dosing frequency. This linear
pharmacokinetic profile combined with the long
half-life of lebrikizumab (19-22 days), in part, ex-
plains the ability to dose lebrikizumab every 4 weeks
and might allow for less frequent dosing during
maintenance. Indeed, the fact that single-dose
groups showed improving placebo-corrected effi-
cacy throughweek 8 suggests the potential for such a
dosing regimen. In contrast, receptor targeting is
associated with target-mediated drug clearance,
which might lead to rapid declines in concentration
after drug discontinuation or interruption, as with
dupilumab, which is dosed every 2 weeks.28
The results of this proof-of-concept study suggest
that IL-13emediated signaling pathways play an
important role in the pathogenesis of AD, and the
blockade of this cytokine could lead to significant
clinical benefit. Patients with moderate-to-severe AD
showed improvements with lebrikizumab treatment,
even with single doses and twice daily TCS use.
However, the twice-daily use of TCS before and
during this trial in all study groups impaired the
ability to fully assess the efficacy of lebrikizumab in
AD, and monotherapy studies may be needed to
assess the efficacy of lebrikizumab. The dose-
response relationships and kinetics of response
observed in this study suggest that future studies of
longer duration with loading, higher and potentially
less frequent dosing, and a larger population on
different (or without) background regimenswill help
clarify the role of targeting IL-13 with lebrikizumab
in AD.We thank Jingyuan Chen and Simon Luo for their
support with statistical programming of the data in this
manuscript. We thank Nicholas Vlahakis for his support in
the design and conduct of the TREBLE study.We also thank
the patients who participated in this study, as well as the
investigators and staff at all study sites. A complete list of
sites from the trial is provided in Supplemental Table IV
(available at http://www.jaad.org). Editorial assistancewas
provided by Wemimo Omotosho, PhD, of MediTech
Media, funded by Genentech. All authors contributed to
the analysis and interpretation of the data and the critical
revision of the report; are accountable for the accuracy and
integrity of the report; and provided final approval to
submit.
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SUPPLEMENTARY APPENDIX
SUPPLEMENTARY METHODS
Study design
This study included a 2-week topical corticoste-
roid (TCS) run-in period prior to the 12-week
treatment period, with the goal of standardizing the
background therapy before randomization and
demonstrating failure to respond to TCS alone. To
assess TCS adherence, patients were required to
record medication use in e-Diary devices.
The study was undertaken in accordance with
Good Clinical Practice guidelines and adhered to the
Declaration of Helsinki. All study documents and
procedures were approved by the appropriate insti-
tutional review boards and ethics committees at each
study site, and each patient provided written
informed consent before study participation. An
internal monitoring committee was incorporated to
monitor patient safety throughout the study.
Patients
Eligible patients had a diagnosis of moderate-to-
severe AD as graded by the Rajka- Langeland criteria
present for at least 1 year at screening.
In addition to those stated in the manuscript, key
exclusion criteria included past and/or current use of
any IL-13 or IL-4/IL-13 monoclonal antibody and a
clinically significant abnormality on screening elec-
trocardiogram or laboratory tests.
Randomization and masking
Three active doses were included to characterize
both exposureeresponse relationships and dosing
frequency requirements. A blocked randomization
scheme stratified by regionwas usedwith a block size
of 4. To maintain blinding, a placebo arm was
included, and all patients were administered 2 pre-
filled syringes on day 1. Placebo patients received two
1-mL syringes filled with placebo, lebrikizumab
125 mg patients received one 1-mL syringe of lebriki-
zumab 125 mg/mL and one 1-mL syringe of placebo,
and lebrikizumab 250 mg patients received two 1-mL
syringes of lebrikizumab 125 mg/mL. All randomized
patients receiveda total of 4 subcutaneous injections: 2
on day 1, 1 on day 29, and 1 on day 57, ie, 3 doses of
study drug (lebrikizumab or placebo) over the first
8 weeks of the 12-week blinded treatment period.
Placebo was prepared with the same formulation as
lebrikizumabwithout addition of the active agent, and
both formulations were identical in appearance.
Procedures
Assessments occurred on weeks 1, 4, 6, 8, and 12
during the 12-week treatment period. Days 1, 29, and
57 (weeks 1, 4, and 8) were treatment days, during
which assessments were carried out before study
drug administration. The Dermatology Life Quality
Index and Atopic Dermatitis Impact Questionnaire
(ADIQ) were self-administered at the study site
before other nonpatient-reported outcome assess-
ments. A study completion visit was performed at the
end of week 20. The use of TCS other than that
provided was prohibited.
As anaphylaxis, anaphylactoid, and hypersensi-
tivity reactions are considered a potential risk with all
biologic medications, all potential cases were iden-
tified and sent for adjudication by an independent
lebrikizumab Anaphylaxis Adjudication Committee.
Pharmacokinetics
Serum samples for analysis of lebrikizumab phar-
macokinetics were obtained in all patients at day 1
(pre-dose) and at weeks 1, 4 (pre-dose), 6, 8 (pre-
dose), 12, 16, and 20 for all dosing regimens. Serum
lebrikizumab concentrations were summarized by
treatment and visit by using descriptive statistics for
the patients that received 1 of the lebrikizumab
treatment regimens. The reported pharmacokinetic
parameters included the week 1 Cmax; Cmin at weeks
4, 8, and 12; and the elimination half-life.
Outcomes
In addition to those stated in the manuscript, key
secondary efficacy endpoints included the percent
change from baseline in Eczema Area and Severity
Index (EASI) score at week 12; percent change from
baseline in SCORing Atopic Dermatitis (SCORAD) at
week 12; percent change from baseline in total %
body surface area (BSA) affected at week 12; percent
change frombaseline in itch as measured by SCORAD
pruritus Visual Analog Scale (VAS) at week 12; and
absolute and percent change in Dermatology Life
Quality Index and ADIQ.
Other analyses included percent change in
SCORAD, sleep loss VAS, as well as percentage of
patients with an absolute change in pruritus VAS $3
from baseline, where the threshold of 3was based on
the minimum clinically important difference for that
instrument.
The ADIQ is an atopic dermatitis (AD)especific
measure of health-related quality of life for use in
patients aged $12 years, developed by Genentech/
Roche following US Food and Drug Administration
patient-reported outcome Guidance (2009).
Statistical analyses
Enrollment of 50 patients per treatment groupwas
estimated to provide at least 90% power to detect a
40% difference in the proportion of patients with
EASI-50 between each lebrikizumab group and the
placebo group at week 12, under the assumption of a
two-sided type I error rate of 0.05, a dropout rate of
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20%, and an EASI-50 rate at week 12 in the placebo
group of ;20%.
Statistical analyses of all endpoints related to a
binary outcome used the same methodology as
described for the primary endpoint. Point estimates
of the proportions by treatment group, correspond-
ing differences from placebo, and associated two-
sided 95% confidence intervals (CIs) for differences
in proportions were provided.
Change from baseline for continuous endpoints
was analyzed by using a mixed-effects model for
repeat measures, including fixed effects of baseline
value, treatment group, visit, treatment by visit
interaction, and geographic region; the variable
patient was included in the model as random effects
with unstructured covariance structure. Missing data
were implicitly imputed by the model (assuming
missing at random). The 95% CIs and two-sided P
values were reported for all secondary efficacy
endpoints. No adjustments for multiplicity were
made. All analyses were performed using SAS. An
internal monitoring committee was incorporated to
monitor patient safety throughout the study.
SUPPLEMENTARY RESULTS
Trial patients
A total of 294 patients were assessed for eligibility;
82 were ineligible and 212 patients were random-
ized. Of the 212 patients randomized, 209 received
study drug. Among enrolled and treated patients, the
mean age (standard deviation) at baseline was
36.1 6 12.6 years; 35% were women and 72% were
white. Patients had on average 47% of their BSA
affected, an average SCORAD of 59, and an EASI of
25. These baseline severity scores were already
improved in comparison to screening due to the
2-week run-in period with twice-daily TCS applica-
tion (Supplemental Table II). The most common
reason for screen failure (26 of 82 [31.7%] screen-
failed patients) was patients not meeting the
inclusion criterion of EASI score $14 due to im-
provements in EASI score during the run-in period.
Efficacy during safety follow-up
Overall, exploratory analyses showed that the
proportion of patients maintaining EASI-50 (90.5%),
EASI-75 (75.0%), and IGA 0 or 1 (70.6%) responses
with lebrikizumab 125 mg every 4 weeks from week
12 to week 20 followed a similar pattern to that
observed at week 12 (Supplemental Table V). Dose-
dependent responses were also observed for percent
change from baseline pruritus VAS at week 20.
Pharmacokinetics
The mean pharmacokinetic parameters and
respective standard deviations for each of the
lebrikizumab dosing regimens are shown in
Supplemental Table VI (available at http://www.
jaad.org). As expected, the pharmacokinetics of
lebrikizumab in AD patients were linear and dose-
proportional over the dose range tested. The phar-
macokinetics of lebrikizumab was also consistent
with that of previous studies in adult asthma,S1-S4
showing linear, dose-proportional characteristics
with a half-life of 19-22 days.
Safety
The rate of injection-site reactions was low in both
the lebrikizumab-treated and placebo groups (1.3%
and 1.9%, respectively). Herpes infections occurred
infrequently and only in lebrikizumab-treated patients
(6 [3.8%]; herpes simplex in 4 [2.6%], and herpes zoster
in 2 [1.3%]); all events were nonserious, mild in
intensity, and resolved by the end of the study. There
were no events of eczema herpeticum. Five (3.2%)
lebrikizumab-treated patients reported eosinophil-
associated adverse events (AEs; 3 events of eosino-
philia and 2 events of eosinophil count increased); all
events were nonserious and mild-to-moderate in in-
tensity. There were no associated clinical symptoms
noted with these 5 AEs. The maximum eosinophil
count in these 5 patients ranged 1.0-3.2 3 109/L; of
these, 3 were grade 2 eosinophilia (1501-5000 cell/
mm3). The increases observed were in line with what
has been seen in previous lebrikizumab studies.S2,S5
Given the previous imbalances reported in biologic
trials in AD,S6 we evaluated conjunctivitis. A total of 15
(9.6%)patients in thepooled lebrikizumabgroupand4
patients (7.5%) in the placebo group had conjunctivitis
as an AE; all events were nonserious, none led to
treatment discontinuation, and there was not a dose-
response relationship.
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Supplemental Fig 1. Atopic dermatitis patient disposition for the TREBLE study. Q4W, Every
4 weeks; SD, single dose.
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Supplemental Table I. Summary of primary and secondary efficacy outcomes for patients with atopic
dermatitis taking lebrikizumab at week 12
Efficacy endpoint
Lebrikizumab
125 mg single dose,
n = 52
Lebrikizumab
250 mg single
dose, n = 53
Lebrikizumab
125 mg Q4W, n = 51 Placebo, n = 53
Primary endpoint
EASI-50
% patients 69.2 69.8 82.4 62.3
D (95% CI) 7.0 (11.1 to 25.1) 7.5 (10.4 to 25.5) 20.1 (3.4 to 36.8)
P value .48 .44 .026
Secondary endpoints
IGA 0 or 1
% patients 21.2 28.3 33.3 18.9
D (95% CI) 2.3 (13.0 to 17.6) 9.4 (6.6 to 25.5) 14.5 (2.2 to 31.2)
P value .77 .26 .098
EASI-75
% patients 38.5 49.1 54.9 34.0
D (95% CI) 4.5 (13.9 to 22.9) 15.1 (3.4 to 33.6) 20.9 (2.3 to 39.6)
P value .66 .12 .036
EASI score, % change from baseline
Adjusted mean (SE) 58.5 (5.36) 57.7 (5.26) 70.5 (5.45) 53.1 (5.38)
D (95% CI) 5.3 (20.3 to 9.7) 4.6 (19.4 to 10.3) 17.4 (32.5 to 2.2)
P value .48 .55 .025
SCORAD-50
% patients 34.6 47.2 51.0 26.4
D (95% CI) 8.2 (9.4 to 25.8) 20.8 (2.8 to 38.7) 24.6 (6.4 to 42.7)
P value .38 .030 .012
SCORAD, % change from baseline
Adjusted mean (SE) 38.7 (4.14) 42.6 (4.07) 53.5 (4.22) 35.4 (4.16)
D (95% CI) 3.3 (14.9 to 8.3) 7.2 (18.7 to 4.3) 18.0 (29.7 to 6.4)
P value .57 .22 .0026
Total % BSA affected, % change from baseline
Adjusted mean (SE) 45.2 (8.21) 38.6 (8.07) 57.7 (8.35) 47.4 (8.24)
D (95% CI) 2.2 (20.7 to 25.1) 8.8 (13.9 to 31.6) 10.3 (33.4 to 12.9)
P value .85 .45 .38
Pruritus (VAS), % change from baseline
Adjusted mean (SE) 34.9 (6.14) 32.8 (5.95) 40.7 (6.19) 27.5 (6.12)
D (95% CI) 7.4 (24.5 to 9.7) 5.3 (22.1 to 11.6) 13.2 (30.3 to 4.0)
P value .40 .54 0.13
Sleep loss (VAS), % change from baseline
Adjusted mean (SE) 53.1 (9.90) 47.2 (9.83) 53.6 (9.49) 22.6 (9.70)
D (95% CI) 30.6 (57.9 to 3.2) 24.6 (51.8 to 2.6) 31.0 (57.8 to 4.2)
P value .029 .076 .023
ADIQ, % change from baseline
Adjusted mean (SE) 33.2 (9.15) 30.8 (8.99) 54.3 (9.17) 29.5 (9.13)
D (95% CI) 3.7 (29.2 to 21.8) 1.3 (26.6 to 24.0) 24.8 (50.3 to 0.7)
P value .77 .92 .057
DLQI, % change from baseline
Adjusted mean (SE) 34.3 (6.93) 40.7 (6.69) 43.1 (7.02) 33.6 (6.93)
D (95% CI) 0.8 (20.0 to 18.5) 7.1 (26.0 to 11.9) 9.6 (28.9 to 9.8)
P value .94 .46 .33
ADIQ, Atopic Dermatitis Impact Questionnaire; BSA, body surface area; CI, confidence interval; DLQI, Dermatology Life Quality Index; EASI-50,
50% reduction in Eczema Area Severity Index; EASI-75, 75% reduction in Eczema Area Severity Index; IGA, Investigator Global Assessment;
Q4W, every 4 weeks; SCORAD, SCORing Atopic Dermatitis; SCORAD-50, 50% reduction in SCORing Atopic Dermatitis; SE, standard error; VAS,
Visual Analog Scale.
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Supplemental Table II. Percent change in EASI, SCORAD, IGA, pruritus VAS, sleep loss VAS and percent BSA
affected from screening to baseline (run-in) in atopic dermatitis patients taking lebrikizumab
Scoring system
Lebrikizumab
125 mg single
dose, n = 52
Lebrikizumab
250 mg single
dose, n = 53
Lebrikizumab
125 mg Q4W,
n = 51
Placebo,
n = 53
All patients,
n = 209
Mean % change in EASI (SDv) 14.3 (27.6) 10.2 (29.2) 9.1 (22.7) 6.4 (32.2) 10.0 (28.1)
Mean absolute change in IGA (SDv) 0.21 (0.50) 0.17 (0.51) 0.14 (0.40) 0.09 (0.45) 0.15 (0.47)
Mean % change in SCORAD (SDv) 12.2 (20.0) 9.9 (14.7) 7.7 (15.0) 5.0 (20.3) 8.7 (17.8)
Mean % change in % BSA affected (SDv) 17.1 (26.7) 4.3 (26.9) 9.3 (27.0) 6.2 (23.2) 9.2 (26.3)
Mean % change in pruritus VAS (SDv) 23.8 (29.6) 15.5 (28.6) 15.2 (39.4) 12.8 (29.8) 16.8 (32.1)
Mean % change in sleep loss VAS (SDv) 29.0 (43.6) 8.1 (81.8) 12.9 (40.1) 5.4 (57.2) 13.9 (58.2)
BSA, Body surface area; EASI, Eczema Area Severity Index; IGA, Investigator Global Assessment; Q4W, every 4 weeks; SCORAD, SCORing Atopic
Dermatitis; SDv, standard deviation; VAS, Visual Analog Scale.
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Supplemental Table III. Atopic dermatitis. Overview of key safety information, weeks 0 to 20
Adverse events
Lebrikizumab
125 mg single
dose, n = 54
Lebrikizumab
250 mg single
dose, n = 52
Lebrikizumab
125 mg Q4W,
n = 50
All lebrikizumab,
n = 156
Placebo,
n = 53
Patients with $1 AE, n (%) 38 (70) 39 (75) 27 (54) 104 (67) 35 (66)
AE leading to withdrawal from study drug, n (%)* 1 (2) 0 (0) 2 (4) 3 (2) 1 (2)
AE leading to dose modification/interruption, n (%)y 0 (0) 1 (2) 0 (0) 1 (1) 0 (0)
Patients with $1 SAE, n (%) 3 (6) 0 (0) 2 (4) 5 (3) 2 (4)
SAE leading to withdrawal from study drug, n (%) 0 (0) 0 (0) 1 (2)
(Myopathy)
1 (1) 0 (0)
AEs of interest/events to be monitored, n (%)
Adjudicated anaphylaxis per Sampson criteriaz 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Infections 24 (44) 20 (39) 12 (24) 56 (36) 24 (45)
Injection site reactions 0 (0) 0 (0) 2 (4) 2 (1) 1 (2)
Malignancies 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Skin infections, n (%)
Patients with skin infection 6 (11) 5 (10) 3 (6) 14 (9) 9 (17)
Herpes infections
Patients with $1 infection, n (%) 1 (2) 3 (6) 2 (4) 6 (4) 0 (0)
Total number of infections related to study drugx 0 0 0 0 0
Herpes simplex, n (%) 1 (2) 2 (4) 1 (2.0) 4 (3) 0 (0)
Herpes zoster, n (%) 0 (0) 1 (2) 1 (2.0) 2 (1) 0 (0)
Conjunctival infections, irritations, and inflammations
Patients with $1 AE, n (%) 7 (13) 5 (10) 3 (6) 15 (10) 4 (8)
Total number of events 8 6 4 18 4
Conjunctivitis allergic, n (%) 4 (7) 2 (4) 2 (4) 8 (5) 0 (0)
Conjunctival hyperaemia, n (%) 0 (0) 1 (2) 0 (0) 1 (1) 0 (0)
AE, Adverse event; Q4W, every 4 weeks; SAE, serious adverse event.
*The following AEs led to withdrawal from study drug: skin infection in the 125 mg single dose group, anxiety and myopathy in 125 mg
Q4W group, and atopic dermatitis in the placebo group.
yOne (1%) patient in the 250 mg single dose lebrikizumab group experienced an AE (gastrointestinal viral infection) that led to dose
interruption.
zMembers of the lebrikizumab Anaphylaxis Adjudication Committee reviewed blinded data to adjudicate cases as anaphylaxis per Sampson
criteria.
xInfections related to study drug were investigator-assessed.
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Supplemental Table IV. Principal investigator sites for TREBLE study
Site number Investigator Center
267701 *Simon, Dagmar Inselspital Bern; Dermatologie, Freiburgstrasse, 3000, Bern, Switzerland
267730 *Remitz, Anita Helsinki University Central Hospital; Skin & Allergy Hospital, Meilahdentie 2, PO
Box 160, 00029, Helsinki, FinlandReitamo, Sakari
267731 *Snellman, Erna Tampere University Hospital; Dermatology and Allergology, Teiskontie 35,
Rakennusosa H, 33520, Tampere, Finland
267732 *Lammintausta, Kaija Turku Central University Hospital; Dermatology and Allergology, H€ameentie 11
(Post Address PL52, 20521 Turku), 20250, Turku, Finland
268162 *de Bruin, Marjolein Umc Utrecht; Dermatology, Heidelberglaan 100, Huispostnr.: F02.127, 3584 Cx,
Utrecht, NetherlandsBruijnzeel-Koomen, C.A.F.M.
268163 *Schuttelaar, M.L.A. University Medical Center Groningen; Department of Dermatology, Hanzeplein
1, De Brug, Room 2.084. Mailcode AB21 PO Box 30.001, 9700RB, Groningen,
Netherlands
268592 *Spuls, Phyllis Academisch Medisch Centrum Universiteit Amsterdam; Dermatology and VU
University Medical Center, Meibergdreef 9, 1100 DD, Amsterdam,
Netherlands
275003 *Solomon, James Ameriderm Research, 725 West Granada Boulevard, Suite 44, Ormond Beach, FL,
32174, United States
275005 *Maari, Catherine Innovaderm Research Inc., 1851 Sherbrooke St. East, Suite 502, L2K 4L5,
Montreal, Quebec, CanadaNigen, Simon
275031 *Raman, Mani The Centre for Dermatology, 312 Highway 7 East, L4B 1A5, Richmond Hill,
Ontario, Canada
275032 *Papp, Kim K. Papp Clinical Research Inc., 135 Union Street East, N2J 1C4, Waterloo, Ontario,
Canada
275033 *Sadick, Neil Sadick Research Group, 911 Park Avenue, Suite 1a, New York, NY, 10075, United
States
275034 *Gooderham, Melinda Dr. Melinda Gooderham Medicine Professional Corporation, 775 Monaghan
Road South, K9J 5K2, Peterborough, Ontario, Canada
275035 *Davis, Steven Dermatology Clinical Research Center of San Antonio, 7810 Louis Pasteur Drive,
Suite 200, San Antonio, TX, 78229, United States
275085 *Dunnick, Cory University of Colorado; Anschutz Cancer Pavilion, 12801 E. 17th Ave., Mail Stop
F703, Room 3232, Aurora, CO, 80045, United StatesArmstrong, April
275088 *Ciliberto, Heather University of Iowa Healthcare; Dermatology, 200 HAWKINS DRIVE, T307-GH,
Iowa City, IA, 52242, United States
275093 *Toth, Darryl Xlr8 Medical Research Inc., 2425 Tecumseh Road East, Suite 210, N8W 1E6,
Windsor, Ontario, Canada
275094 *Pariser, David Virginia Clinical Research Inc., 6160 Kempsville Circle, Suite 200a, Norfolk, VA,
23502, United States
275095 *Sofen, Howard Dermatology Research Associate, 8930 S. Sepulveda Blvd., Suite 114, Los
Angeles, CA, 90045, United States
275193 *Adams, Stewart Institute for Skin Advancement, 4935 40th Avenue NW, Suite 206, Market Mall
Professional Building, T3A 2N1, Calgary, Alberta, Canada
275251 *Silverberg, Jonathan Northwestern University Feinberg School of Medicine, 710 North Lake Shore
Drive; Abbott Hall, Room 1123, Chicago, IL, 60611, United States
275253 *Hebert, Adelaide University of Texas Medical School-Houston, 6655 Travis, Suite 600, Houston,
TX, 77030, United States
275371 *Simpson, Eric Oregon Health & Science University; Department of Dermatology, 3303 SW
Bond Ave., Mail Code: CH16D, Portland, OR, 97239-4501, United States
275372 *Murakawa, George Somerset Skin Centre, 255 Kirts Blvd., Troy, MI, 48084, United States
275758 *Foley, Peter Skin & Cancer Foundation, Level 1 80 Drummond St, 3053, Carlton, Victoria,
Australia
275792 *Sheu, Hamm-Ming National Cheng-Kung University Hospital; Department of Dermatology, 138
Sheng-Li Road, 70403, Tainan, Taiwan
275793 *Chu, Chia-Yu National Taiwan University Hospital; Department of Dermatology, 2F, No.1,
Changde St, Zhongzheng District, 10048, Taipei, Taiwan
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275794 *Lee, Chih-Hung Chang Gung Medical Foundation; Kaohsiung Branch; Department of
Dermatology, No.123, Dapi Road, Niaosng District, 83301, Kaohsiung, Taiwan
276106 *Varigos, George Royal Melbourne Hospital; Dermatology Department, Grattan St., Level 2 East
Main Block Room E200, 3050, Parkville, Victoria, Australia
276128 *Bzdulska-Doskocz, Beata ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. Z O. O, Ul. PCK 26,
33-100, Tarnow, Poland
276143 *Gebauer, Kurt Fremantle Dermatology, 229 High Street, 6160, Fremantle, Western Australia,
Australia
276145 *Shumack, Stephen St George Dermatology and Skin Cancer Centre, Level 3, 22 Belgrave Street,
2217, Kogarah, New South Wales, Australia
276180 *Nowicki, Roman Uniwersyteckie Centeum Kliniczne Gumed; Klinika Dermatologii, Wenerologii I
Alergologii, Ul. Kliniczna 1a, 80-402, Gdansk, Poland
276182 *Turek-Urasinska, Katarzyna Laser Clinic, Al. Piastow 65 U5, 70-322, Szczecin, Poland
276231 *Weglowska, Jolanta Dermmedica Sp.Z O.O., Ul. Zakrzowska 19a, 51-318, Wroclaw, Poland
276356 *Filipovska, Olga Masarykova Nemocnice O.Z; Kozni Oddeleni, Socialni Pece 3316/12A, 401 13,
Usti Nad Labem, Czech Republic
276372 *Pizinger, Karel Faculty Hospital; Department of Dermatology, E. Benese 13, 305 99, Plzen,
Czech Republic
276373 *Arenberger, Petr Charles University School of Medicine; Department of Dermatology, Srobarova
50, 100 34, Prague 10, Czech Republic
276469 *Hong, Chih-ho Guildford Dermatology Specialists, 15300 105 Avenue, Suite 20, V3R 6A7,
Surrey, British Columbia, Canada
276983 *Seo, SeongJun Chungang University Hospital, 102, Heukseok-Ro, Dongjak-Gu, 06973, Seoul,
Republic of Korea
276984 *Lee, Kwang-Hoon Severance Hospital, Yonsei University Health System, 50 Yonsei-Ro,
Seodaemun-Gu, 03722, Seoul, Republic of Korea
276985 *Kim, KyuHan Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu, 03080, Seoul,
Republic of Korea
277723 *Di Lucca, Julie CHUV; Dermatologie, Avenue de Beaumont 29, 1011, Lausanne, Switzerland
277776 *Espa~na, Agustın Clinica Universitaria de Navarra; Servicio de Dermatologia, Avenida Pio XII, 36,
31008, Pamplona, Navarra, Spain
277780 *Puig, Luis Hospital de la Santa Creu I Sant Pau; Servicio de Dermatologia, Sant Antoni
Maria Claret, 167, 08025, Barcelona, Spain
277784 *Vilata, Juan Jose Hospital General Universitario de Valencia; Servicio de Dermatologıa, Av. Tres
Cruces S/N, Pabellon B Planta Baja, 46014, Valencia, Valencia, Spain
277801 *Bhutani, Tina University of Calif-San Francisco, 1701 Divisadero Street, Rm 430, San Francisco,
CA, 94115, United States
277803 *Sanchez Perez, Javier Hospital Universitario La Princesa, Servicio Dermatologia, C/Diego de Leon, 62,
28006, Madrid, Madrid, Spain
277804 *Perez, Bibiana Hospital Ramon y Cajal; Servicio Dermatologia, Ctra. de Colmenar Viejo, Km.
9,100, 28034, Madrid, Madrid, Spain
277936 *Herranz, Pedro Hospital Universitario La Paz; Servicio de Dermatologia, Paseo de la Castellana
261, 28046, Madrid, Madrid, Spain
278387 *Bieber, Thomas Universit€atsklinik Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany
278389 *Kaatz, Martin SRH Wald-Klinikum Gera Gmbh; Hautkrankheiten und Allergologie, Strasse Des
Friedens 122, 07548, Gera, Germany
278391 *Pinter, Andreas Klinik Johann Wolfgang von Goethe Uni; Klinik F€ur Dermatologie, Venerologie
und Allergologie, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
278570 *Smith, Catherine Guy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital; Skin Therapy
Research Unit, Great Maze Pond, 1st Floor Counting House, London, SE1 9RT,
United Kingdom
278571 *Reynolds, Nick Newcastle University & The Newcastle upon Tyne Hospitals NHS Foundation
Trust, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom
278572 *Ladoyanni, Evmorfia Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, United Kingdom
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278573 *Griffiths, Christopher Salford Royal NHS Foundation Trust, Stott Lane, Barnes Building, Salford, M6
8HD, United Kingdom
278574 *August, Suzannah Poole Hospital, Poole Hospital NHS Trust, Longfleet Road, Poole, BH15 2JB,
United Kingdom
278575 *Ogg, Graham Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ, United Kingdom
279099 *Grande, Sophie Centre Hospitalier Lyon Sud; Dermatologie, Pavillon Medical, PC Medicaux
3eme Etage, 69495, Pierre Benite, France
280047 *Lacour, Jean Phillippe Hopital L Archet 2; Ginestriere, Service de Dermatologie, 151, Rue Saint-Antoine
De, BP 3079, 06200, Nice Cedex 3, France
280208 *Taieb, Alain Hopital Saint Andre Chu De Bordeaux; Dermatologie, 1, Rue Jean Burguet,
33075, Bordeaux, France
*Indicates the current Principal Investigator. The names of previous Principal Investigators, if any, are also listed.
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Supplemental Table V. Key efficacy outcomes of atopic dermatitis patients taking lebrikizumab at week 20
Outcomes
Lebrikizumab
125 mg single dose
Lebrikizumab
250 mg single dose
Lebrikizumab
125 mg Q4W Placebo
Patients maintaining EASI-50 response from week 12 to week 20
N (%) 29/36 (80.6) 29/37 (78.4) 38/42 (90.5) 24/33 (72.7)
Placebo-corrected differences (SE) 7.8 5.7 17.8
P value .39 .58 .047
Patients maintaining EASI-75 response from week 12 to week 20
N (%) 9/20 (45.0) 16/26 (61.5) 21/28 (75.0) 12/18 (66.7)
Placebo-corrected differences (SE) 21.7 5.1 8.3
P value .20 .81 .54
Patients maintaining IGA 0 or 1 response from week 12 to week 20
N (%) 6/11 (54.5) 9/15 (60.0) 12/17 (70.6) 6/10 (60)
Placebo-corrected differences (SE) 5.5 0 10.6
P value .97 .94 .58
Patients maintaining SCORAD-50 response from week 12 to week 20
N (%) 11/18 (61.1) 16/25 (64.0) 13/26 (50.0) 11/14 (78.6)
Placebo-corrected differences (SE) 17.5 14.6 28.6
P value .34 .49 .13
Percent change from baseline in EASI
Adjusted mean % change (SE) 62.1 (5.43) 55.9 (5.28) 71.1 (5.50) 54.1 (5.49)
Placebo-corrected differences (95% CI) 8.1 (23.3 to 7.1) 1.9 (16.9 to 13.2) 17.1 (32.4 to 1.7)
P value .30 .81 .03
Percent change from baseline in the % BSA affected
Adjusted mean % change (SE) 53.6 (6.10) 46.4 (5.96) 63.8 (6.19) 52.0 (6.16)
Placebo-corrected differences (95% CI) 1.6 (18.7 to 15.5) 5.6 (11.4 to 22.5) 11.8 (29.0 to 5.5)
P value .85 .52 .18
Percent change from baseline pruritus VAS
Adjusted mean % change (SE) 27.6 (7.64) 30.3 (7.36) 35.2 (7.68) 21.5 (7.66)
Placebo-corrected differences (95% CI) 6.1 (27.5 to 15.2) 8.8 (29.7 to 12.2) 13.8 (35.2 to 7.6)
P value .57 .41 .21
BSA, Body surface area; CI, confidence interval; EASI-50, 50% reduction in Eczema Area Severity Index; EASI-75, 75% reduction in Eczema Area
Severity Index; IGA, Investigator Global Assessment; Q4W, every 4 weeks; SCORAD-50, 50% reduction in SCORing Atopic Dermatitis; SE,
standard error; VAS, Visual Analog Scale.
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Supplemental Table VI. Mean lebrikizumab pharmacokinetic parameters after single or multiple dose
subcutaneous administration in atopic dermatitis patients
Pharmacokinetic parameter Lebrikizumab 125 mg single dose Lebrikizumab 250 mg single dose Lebrikizumab 125 mg Q4W
Mean Cmax, wk1 g/mL (SDv) 17.0 (5.22) 35.6 (10.8) 16.1 (5.19)
Mean Cmin, wk4 g/mL (SDv) 10.2 (3.00) 21.4 (6.87) 9.15 (2.99)
Mean Cmin, wk8 g/mL (SDv) 4.59 (2.12) 9.53 (3.53) 13.6 (5.34)
Mean Cmin, wk12 g/mL (SDv) 2.28 (1.72) 3.77 (2.01) 14.4 (5.69)
t1/2, day 18.5 (5.06) 22.2 (6.18) 20.9 (4.17)
Cmax, wk1, Maximum lebrikizumab concentration at week 1; Cmin, wk4, observed minimum concentration at week 4; Cmin, wk8, observed
minimum concentration at week 8; Cmin, wk12, observed minimum concentration at week 12; Q4W, every 4 weeks; SDv, standard deviation;
t1/2, elimination half-life.
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